After experimenting with value-based contracts over the past three to four years, US payers are shifting their deal-making focus from chronic use drugs to high-cost agents like cell and gene therapy. The change reflects payers’ growing sense that value-based or outcomes-based contracts for chronic use therapies can be more trouble to hammer out than they are worth. Another driving factor is that highly expensive gene therapies are beginning to reach the market, more are coming, and collectively they are expected to pose a serious reimbursement challenge.
The value-based purchasing environment has matured over the last four years, where before there was more talk than actual contracting....
